Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trialChristoph Röllig, Gerhard Ehninger, Hubert Serve et al.|The Lancet Oncology|2015Cited by 402
P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)Katja Sockel, Uwe Platzbecker, Richard Noppeney et al.|HemaSphere|2023Cited by 0